Table 1.
Prospective studies examining mobile sensor data and clinical outcomes in oncology patients.
| Author and yearref | Number of patients | Mean/median age | Type of patients | Device(s) used | Timing | Outcome |
|---|---|---|---|---|---|---|
| Bennett et al.24 | 32 | 55 | Hematopoietic stem cell transplant | Fitbit Flex | During transplant hospitalization and 4 weeks post-discharge | PRO-CTCAE for toxicities and symptoms and PROMIS physical health, mental health, and quality of life |
| Bade et al.25 | 39 | 66 | Advanced lung cancer | Fitbit Zip | For 7 days at varying points in treatment | EORTC QLQ-30 quality of life, PHQ-9 depressive symptoms, MMRC dyspnea scale |
| Gupta et al.26 | 24 | 54 | Mixed cancer | Fitbit Flex | 12 weeks during systemic therapy | ECOG Performance Status, FACT-G quality of life, QIDS-SR16 depressive symptoms, BFI fatigue |
| Ohri et al.27 | 50 | 66 | Locally advanced non-small cell lung cancer | Garmin Vivofit | Before start of chemoradiation therapy to completion of the first week (median 17 days) | Hospitalization during radiation, completion of radiation without delay, progression-free and overall survival |
| Ohri et al.28 | 38 | 64 | Head and neck, lung, and gastrointestinal cancer | Garmin | During concurrent chemoradiotherapy | Unplanned hospitalization during treatment |
| Low et al.29 | 71 | 57 | Metastatic peritoneal cancer | Fitbit Flex or Charge | During inpatient recovery from cytoreductive surgery with hyperthermic intraperitoneal chemotherapy | 30- and 60-day readmission |
| Sun et al.30 | 20 | 56 | Hepatobiliary and gastrointestinal cancer | Garmin Vivovit 2 | 3–7 days before surgery, during inpatient recovery, and up to two weeks following discharge | 30-day comprehensive complication Index based on Clavien-Dindo classification |
| Gresham et al.31 | 37 | 62 | Mixed advanced cancer | Fitbit Charge HR | 14 days during or awaiting chemotherapy or radiation therapy | Provider-assessed ECOG & Karnofsky performance status, adverse events, hospitalizations, 6-month survival |
| Soto-Perez-de-Delis et al.42 | 40 | 73 | Mixed solid tumors | Android smartphone with Google Fit pedometer app | Before (median 11 days) and during (median 21 days) chemotherapy | Grade 2 or 3 toxicities (commonly fatigue, nausea/vomiting, diarrhea, infections) |
| Panda et al.43 | 62 | 66 | Mixed cancer | iOS or Android smartphone with Beiwe sensing app | Before (median 5 days) and after (median 147 days) cancer surgery | Clinically significant postoperative events |
| Low et al.44 | 14 | 60 | Gastrointestinal cancer | Android smartphone with AWARE sensing app and Fitbit charge HR | Four weeks during chemotherapy | Daily symptom burden |
| Cai et al.45 | 7 | 60 | Breast cancer | iOS or Android smartphone with Sensus sensing app | Seven weeks during active treatment | Daily and weekly mood, anxiety, and depression ratings |
| Wright et al.46 | 10 | 60 | Gynecologic cancer | iOS or Android smartphone with Beiwe sensing app, Fitbit Zip and Charge 2 | 30 days during chemotherapy | Daily PRO-CTCAE toxicities and PROMIS quality of life |
| Pavic et al.47 | 30 | 64 | Metastatic cancer | Everion bracelet by Biovotion plus Samsung Galaxy S5 | 12 weeks starting at discharge from the hospital | Emergency visits, readmissions, and deaths |